Company: PRTC
Filing Date: 2025-04-30
Form Type: 20-F
Source: 0001782999-25-000005
Chunk: 81

Company: PureTech Health plc
Filing Date: 2025-04-30
Form: 20-F
Item: Item 10
Chunk 81
---
 similar rights;
•The Backstop Agreement between CPSR and us, among others, dated December 30, 2021;
•Subscription Agreement between CPSR and the investor parties thereto dated July 19, 2021; 
•Amended and Restated Investors’ Rights Agreement between Vor and the investor parties named therein, dated June 30, 2020; and
•Amended and Restated Investors’ Rights Agreement between Seaport and the investor parties thereto, dated October 18, 2024, the execution of which replaced and terminated the previous Amended and Restated Investors' Rights Agreement dated April 8, 2024, which had provided us with similar rights. The Amended and Restated Investors' Rights Agreement grants us a preemptive right to purchase our pro rata share of new securities that Seaport may propose to sell and issue, subject to certain exceptions. We also have the right, following the completion of an initial public offering, to demand that Seaport file a registration statement or request that our shares be covered by a registration statement that Seaport is filing in certain circumstances. The agreement also provides us with certain information and inspection rights, which rights terminate upon an initial public offering or certain liquidation events. 
We have certain preemptive rights of first refusal with respect to transfers of shares by other holders pursuant to the following agreements:
•Fifth Amended and Restated Right of First Refusal and Co-Sale Agreement, dated July 19, 2019, by and among Follica, Incorporated and the investors and key holders party thereto;
•Amended and Restated Right of First Refusal and Co-Sale Agreement, dated May 25, 2022, by and between Sonde Health, Inc. and the investors and key holders party thereto, the execution of which replaced and terminated the previous Right of First Refusal and Co-Sale Agreement dated April 9, 2019, which had provided us with similar rights; 
•Right of First Refusal and Co-Sale Agreement, dated December 18, 2017, by and between Entrega, Inc. and the investors and key holders party thereto; and
•Amended and Restated Right of First Refusal and Co-Sale Agreement, dated October 18, 2024, by and between Seaport Therapeutics, Inc. and the investors and key holders party thereto, the execution of which replaced and terminated the previous Right of First Refusal and